Adding One Year of Palbociclib to Adjuvant Endocrine Treatment Does Not Improve OS or iDFS in High-Risk HR-positive, HER2-negative Primary Breast Cancer By Ogkologos - April 8, 2025 653 0 Facebook Twitter Google+ Pinterest WhatsApp Final survival results from the PENELOPE-B study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR The Potential of AI to Improve Cancer Care is Only Going... October 16, 2023 FDA Approves Acalabrutinib with Bendamustine and Rituximab for Previously Untreated Mantle... February 21, 2025 How Pelvic Floor Therapy Can Help People With Prostate Cancer and... December 13, 2022 Dress up that Salad! December 21, 2020 Load more HOT NEWS How NatWest Group are making a difference this Giving Tuesday Meet the teams tackling 5 challenges in children’s and young people’s... BRCA1/2 Pathogenic Variant Carriers with Serous Tubal Intraepithelial Carcinoma at Risk-Reducing... 11 Sun Safety Myths Debunked
